| 000 | 01637 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514232335.0 | ||
| 264 | 0 | _c20051011 | |
| 008 | 200510s 0 0 eng d | ||
| 022 | _a0149-2918 | ||
| 024 | 7 |
_a10.1016/s0149-2918(05)00090-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWeycker, Derek | |
| 245 | 0 | 0 |
_aRetrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bClinical therapeutics _cMay 2005 |
||
| 300 |
_a646-56 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xeconomics |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xeconomics |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xeconomics |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aInsurance Coverage |
| 650 | 0 | 4 | _aInsurance, Health |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aYu, Elaine B | |
| 700 | 1 | _aWoolley, J Michael | |
| 700 | 1 | _aOster, Gerry | |
| 773 | 0 |
_tClinical therapeutics _gvol. 27 _gno. 5 _gp. 646-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0149-2918(05)00090-1 _zAvailable from publisher's website |
| 999 |
_c15636003 _d15636003 |
||